News - Page 5

Forma Life Sciences, which inherited BioDuro’s California operations earlier this year, officially launched as a CDMO with a focus on oral solid dosage drugs this week.

BioDuro, headquartered in California, has set up a new joint venture with Taiwan drug ingredients manufacturer, Cenra API Solutions. The new enterprise will see Cenra’s commercial-scale facility in Taipei folded into BioDuro’s

Quotient Sciences, a CDMO that specializes in “niche and smaller volume” drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the

In a Worker Adjustment and Retraining Notification Act alert filed this week, Merck revealed that it is laying off 147 staffers at a vaccine manufacturing plant in Durham. The cuts are a

Viatris’ three-year reorganization will affect staffers in a range of functions including the company’s commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.

The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company’s plan to infuse $100 billion into its American operations over

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner speaks with Atradius’ Brady McKinney about how tariff pressures drove a 2025 manufacturing surge in pharma and why production is expected